— Know what they know.
Not Investment Advice

SNSE NASDAQ

Sensei Biotherapeutics, Inc.
1W: +6.5% 1M: -30.1% 3M: -53.7% YTD: +43.5% 1Y: +106.4% 3Y: -49.5% 5Y: -94.3%
$13.85
Last traded 2026-06-15 — delisted
NASDAQ · Healthcare · Biotechnology · $18.6M mcap · 811874 float · 6.42% daily turnover · Short 40% of daily vol

Balance Sheet Trends

Total Assets
$23M -49.5% ▼
5Y CAGR: +1.3%
Total Liabilities
$4M -38.2% ▼
5Y CAGR: -4.9%
Shareholders Equity
$19M -51.6% ▼
5Y CAGR: +3.2%
Cash & Investments
$21M -48.8% ▼
5Y CAGR: +5.0%
Total Debt
$2M -60.8% ▼
5Y CAGR: +17.1%
Net Debt
-$7M -16.4% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$7M$18M$13M$10M$9M
Short-Term Investments$140M$89M$53M$31M$13M
Cash & ST Investments$148M$107M$66M$41M$21M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$374K$344K$325K$120K$323K
Total Current Assets$149M$109M$67M$42M$22M
Property, Plant & Equip.$5M$10M$7M$3M$1M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$39K$63K$86K$48K$18K
Total Non-Current Assets$5M$10M$7M$3M$1M
Total Assets$153M$118M$74M$45M$23M
— Liabilities —
Accounts Payable$2M$4M$2M$1M$0
Short-Term Debt$0$0$0$2M$1M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$0$0$0$3M
Total Current Liabilities$5M$9M$6M$5M$4M
Long-Term Debt$0$0$0$0$59K
Other Non-Current Liab.$149K$0$67K$0$0
Total Non-Current Liabilities$2M$6M$4M$2M$59K
Total Liabilities$7M$15M$9M$7M$4M
— Equity —
Common Stock$3K$3K$3K$3K$0
Retained Earnings-$149M-$198M-$232M-$262M-$283M
Accumulated OCI-$333K-$1M-$209K-$13K$1K
Total Stockholders Equity$147M$103M$65M$38M$19M
Total Liabilities & Equity$153M$118M$74M$45M$23M
— Key Metrics —
Total Debt$2M$8M$6M$4M$2M
Net Debt-$5M-$10M-$7M-$6M-$7M
Total Investments$140M$89M$53M$31M$13M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms